Resmed, Inc. (RMD) Tops Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/25/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
Needham & Company Upgrades ResMed (RMD) to Buy
January 23, 2015 6:25 AM ESTNeedham & Company upgraded ResMed (NYSE: RMD) from Hold to Buy with a price target of $77.00 following solid Q3 results as the product cycle drove faster growth.
Analyst Mike Matson comments, "RMD's F2Q15 revenue and EPS beat consensus. RMD's new products drove faster... More
